Karabiber, E. Et Al. 2022. Hyperamylasemia During Omalizumab Therapy. ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1 , 31-35.

Karabiber, E., Aktas, O. O., Ozdemir, E., DAMADOĞLU, E., ŞAHİNER, Ü. M., KARAKAYA, G., ... KALYONCU, A. F.(2022). Hyperamylasemia During Omalizumab Therapy. ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1, 31-35.

Karabiber, Esra Et Al. "Hyperamylasemia During Omalizumab Therapy," ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1, 31-35, 2022

Karabiber, Esra Et Al. "Hyperamylasemia During Omalizumab Therapy." ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1, pp.31-35, 2022

Karabiber, E. Et Al. (2022) . "Hyperamylasemia During Omalizumab Therapy." ASTIM ALLERJI IMMUNOLOJI , vol.20, no.1, pp.31-35.

@article{article, author={Esra Karabiber Et Al. }, title={Hyperamylasemia During Omalizumab Therapy}, journal={ASTIM ALLERJI IMMUNOLOJI}, year=2022, pages={31-35} }